AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$286.01−6.81 (-2.33%)
Close on Nov 18, 2026Market cap $505.41BP/E 80.8Yield 2.33%
AbbVie net income
Net income is the profit left for shareholders after every expense, interest and tax.
AbbVie's net income for the twelve months ending Jun 30, 2026 was $6.31B, up 67.7% year over year. For fiscal 2025 it was $4.23B, down 1.2% from the year before. Over ten years it grew -1.9% a year on average. The highest annual figure on record is $11.84B in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.23B | -1.2% |
| FY2024 | Dec 31, 2024 | $4.28B | -12.0% |
| FY2023 | Dec 31, 2023 | $4.86B | -58.9% |
| FY2022 | Dec 31, 2022 | $11.84B | +2.5% |
| FY2021 | Dec 31, 2021 | $11.54B | +150.0% |
| FY2020 | Dec 31, 2020 | $4.62B | -41.4% |
| FY2019 | Dec 31, 2019 | $7.88B | +38.6% |
| FY2018 | Dec 31, 2018 | $5.69B | +7.1% |
| FY2017 | Dec 31, 2017 | $5.31B | -10.8% |
| FY2016 | Dec 31, 2016 | $5.95B | +15.7% |
| FY2015 | Dec 31, 2015 | $5.14B | +190.0% |
| FY2014 | Dec 31, 2014 | $1.77B | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.61B | +285.2% |
| Q1 FY2026 | Mar 31, 2026 | $695.00M | -46.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.82B | – |
| Q3 FY2025 | Sep 30, 2025 | $186.00M | -88.1% |
| Q2 FY2025 | Jun 30, 2025 | $938.00M | -31.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.29B | -6.1% |
| Q4 FY2024 | Dec 31, 2024 | -$22.00M | -102.7% |
| Q3 FY2024 | Sep 30, 2024 | $1.56B | -12.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.37B | -32.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.37B | +472.8% |
| Q4 FY2023 | Dec 31, 2023 | $822.00M | -66.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.78B | -55.0% |
| Q2 FY2023 | Jun 30, 2023 | $2.02B | +119.0% |
| Q1 FY2023 | Mar 31, 2023 | $239.00M | -94.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.47B | -38.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.95B | +24.2% |
| Q2 FY2022 | Jun 30, 2022 | $924.00M | +20.6% |
| Q1 FY2022 | Mar 31, 2022 | $4.49B | +26.4% |
| Q4 FY2021 | Dec 31, 2021 | $4.04B | +11133.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.18B | +37.7% |
| Q2 FY2021 | Jun 30, 2021 | $766.00M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.55B | +18.0% |
| Q4 FY2020 | Dec 31, 2020 | $36.00M | -98.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.31B | +22.5% |
| Q2 FY2020 | Jun 30, 2020 | -$738.00M | -199.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.01B | +22.6% |
| Q4 FY2019 | Dec 31, 2019 | $2.80B | – |
| Q3 FY2019 | Sep 30, 2019 | $1.88B | -31.4% |
| Q2 FY2019 | Jun 30, 2019 | $741.00M | -62.6% |
| Q1 FY2019 | Mar 31, 2019 | $2.46B | -11.7% |
| Q4 FY2018 | Dec 31, 2018 | -$1.83B | -3611.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.75B | +68.4% |
| Q2 FY2018 | Jun 30, 2018 | $1.98B | +3.6% |
| Q1 FY2018 | Mar 31, 2018 | $2.78B | +62.7% |
| Q4 FY2017 | Dec 31, 2017 | $52.00M | -96.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.63B | +2.1% |
| Q2 FY2017 | Jun 30, 2017 | $1.92B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.71B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.39B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.60B | – |
See a number that looks wrong?